Form 8-K - Current report:
SEC Accession No. 0001104659-25-044838
Filing Date
2025-05-06
Accepted
2025-05-06 08:36:04
Documents
15
Period of Report
2025-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2514104d1_8k.htm   iXBRL 8-K 24100
2 EXHIBIT 99.1 tm2514104d1_ex99-1.htm EX-99.1 50132
6 GRAPHIC tm2514104d1_ex99-1img01.jpg GRAPHIC 3589
  Complete submission text file 0001104659-25-044838.txt   260159

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nvct-20250506.xsd EX-101.SCH 3014
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvct-20250506_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvct-20250506_pre.xml EX-101.PRE 22358
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2514104d1_8k_htm.xml XML 3652
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

EIN.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41264 | Film No.: 25915397
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)